Research resource

Global identification of estrogen receptor β target genes in triple negative breast cancer cells

Erin K. Shanle, Zibo Zhao, John R Hawse, Kari Wisinski, Sunduz Keles, Ming Yuan, Wei Xu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Breast cancers that are negative for estrogen receptor α (ERα), progesterone receptor, and human epidermal growth factor receptor 2 are known as triple-negative breast cancers (TNBC). TNBCs are associated with an overall poor prognosis because they lack expression of therapeutic targets like ERα and are biologically more aggressive. A second estrogen receptor, ERβ, has been found to be expressed in 50% to 90% of ERα-negative breast cancers, and ERβ expression in TNBCs has been shown to correlate with improved disease-free survival and good prognosis. To elucidate the role of ERβ in regulating gene expression and cell proliferation in TNBC cells, the TNBC cell line MDA-MB-468 was engineered with inducible expression of full-length ERβ. In culture, ERβ expression inhibited cell growth by inducing a G1 cell cycle arrest, which was further enhanced by 17β-estradiol treatment. In xenografts, ERβ expression also inhibited tumor formation and growth, and 17β-estradiol treatment resulted in rapid tumor regression. Furthermore, genomic RNA sequencing identified both ligand-dependent and -independent ERβ target genes, some of which were also regulated by ERβ in other TNBC cell lines and correlated with ERβ expression in a cohort of TNBCs from the Cancer Genome Atlas Network. ERβ target genes were enriched in genes that regulate cell death and survival, cell movement, cell development, and growth and proliferation, as well as genes involved in the Wnt/β-catenin and the G1/S cell cycle phase checkpoint pathways. In addition to confirming the anti-proliferative effects of ERβ in TNBC cells, these data provide a comprehensive resource of ERβ target genes and suggest that ERβ may be targeted with ligands that can stimulate its growth inhibitory effects.

Original languageEnglish (US)
Pages (from-to)1762-1775
Number of pages14
JournalMolecular Endocrinology
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Triple Negative Breast Neoplasms
Estrogen Receptors
Research
Genes
G1 Phase Cell Cycle Checkpoints
Estradiol
Growth
Breast Neoplasms
Ligands
RNA Sequence Analysis
Cell Line
Catenins
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Research resource : Global identification of estrogen receptor β target genes in triple negative breast cancer cells. / Shanle, Erin K.; Zhao, Zibo; Hawse, John R; Wisinski, Kari; Keles, Sunduz; Yuan, Ming; Xu, Wei.

In: Molecular Endocrinology, Vol. 27, No. 10, 01.10.2013, p. 1762-1775.

Research output: Contribution to journalArticle

Shanle, Erin K. ; Zhao, Zibo ; Hawse, John R ; Wisinski, Kari ; Keles, Sunduz ; Yuan, Ming ; Xu, Wei. / Research resource : Global identification of estrogen receptor β target genes in triple negative breast cancer cells. In: Molecular Endocrinology. 2013 ; Vol. 27, No. 10. pp. 1762-1775.
@article{1e090a3469604b88a8aa7b1275b6c9f9,
title = "Research resource: Global identification of estrogen receptor β target genes in triple negative breast cancer cells",
abstract = "Breast cancers that are negative for estrogen receptor α (ERα), progesterone receptor, and human epidermal growth factor receptor 2 are known as triple-negative breast cancers (TNBC). TNBCs are associated with an overall poor prognosis because they lack expression of therapeutic targets like ERα and are biologically more aggressive. A second estrogen receptor, ERβ, has been found to be expressed in 50{\%} to 90{\%} of ERα-negative breast cancers, and ERβ expression in TNBCs has been shown to correlate with improved disease-free survival and good prognosis. To elucidate the role of ERβ in regulating gene expression and cell proliferation in TNBC cells, the TNBC cell line MDA-MB-468 was engineered with inducible expression of full-length ERβ. In culture, ERβ expression inhibited cell growth by inducing a G1 cell cycle arrest, which was further enhanced by 17β-estradiol treatment. In xenografts, ERβ expression also inhibited tumor formation and growth, and 17β-estradiol treatment resulted in rapid tumor regression. Furthermore, genomic RNA sequencing identified both ligand-dependent and -independent ERβ target genes, some of which were also regulated by ERβ in other TNBC cell lines and correlated with ERβ expression in a cohort of TNBCs from the Cancer Genome Atlas Network. ERβ target genes were enriched in genes that regulate cell death and survival, cell movement, cell development, and growth and proliferation, as well as genes involved in the Wnt/β-catenin and the G1/S cell cycle phase checkpoint pathways. In addition to confirming the anti-proliferative effects of ERβ in TNBC cells, these data provide a comprehensive resource of ERβ target genes and suggest that ERβ may be targeted with ligands that can stimulate its growth inhibitory effects.",
author = "Shanle, {Erin K.} and Zibo Zhao and Hawse, {John R} and Kari Wisinski and Sunduz Keles and Ming Yuan and Wei Xu",
year = "2013",
month = "10",
day = "1",
doi = "10.1210/me.2013-1164",
language = "English (US)",
volume = "27",
pages = "1762--1775",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Research resource

T2 - Global identification of estrogen receptor β target genes in triple negative breast cancer cells

AU - Shanle, Erin K.

AU - Zhao, Zibo

AU - Hawse, John R

AU - Wisinski, Kari

AU - Keles, Sunduz

AU - Yuan, Ming

AU - Xu, Wei

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Breast cancers that are negative for estrogen receptor α (ERα), progesterone receptor, and human epidermal growth factor receptor 2 are known as triple-negative breast cancers (TNBC). TNBCs are associated with an overall poor prognosis because they lack expression of therapeutic targets like ERα and are biologically more aggressive. A second estrogen receptor, ERβ, has been found to be expressed in 50% to 90% of ERα-negative breast cancers, and ERβ expression in TNBCs has been shown to correlate with improved disease-free survival and good prognosis. To elucidate the role of ERβ in regulating gene expression and cell proliferation in TNBC cells, the TNBC cell line MDA-MB-468 was engineered with inducible expression of full-length ERβ. In culture, ERβ expression inhibited cell growth by inducing a G1 cell cycle arrest, which was further enhanced by 17β-estradiol treatment. In xenografts, ERβ expression also inhibited tumor formation and growth, and 17β-estradiol treatment resulted in rapid tumor regression. Furthermore, genomic RNA sequencing identified both ligand-dependent and -independent ERβ target genes, some of which were also regulated by ERβ in other TNBC cell lines and correlated with ERβ expression in a cohort of TNBCs from the Cancer Genome Atlas Network. ERβ target genes were enriched in genes that regulate cell death and survival, cell movement, cell development, and growth and proliferation, as well as genes involved in the Wnt/β-catenin and the G1/S cell cycle phase checkpoint pathways. In addition to confirming the anti-proliferative effects of ERβ in TNBC cells, these data provide a comprehensive resource of ERβ target genes and suggest that ERβ may be targeted with ligands that can stimulate its growth inhibitory effects.

AB - Breast cancers that are negative for estrogen receptor α (ERα), progesterone receptor, and human epidermal growth factor receptor 2 are known as triple-negative breast cancers (TNBC). TNBCs are associated with an overall poor prognosis because they lack expression of therapeutic targets like ERα and are biologically more aggressive. A second estrogen receptor, ERβ, has been found to be expressed in 50% to 90% of ERα-negative breast cancers, and ERβ expression in TNBCs has been shown to correlate with improved disease-free survival and good prognosis. To elucidate the role of ERβ in regulating gene expression and cell proliferation in TNBC cells, the TNBC cell line MDA-MB-468 was engineered with inducible expression of full-length ERβ. In culture, ERβ expression inhibited cell growth by inducing a G1 cell cycle arrest, which was further enhanced by 17β-estradiol treatment. In xenografts, ERβ expression also inhibited tumor formation and growth, and 17β-estradiol treatment resulted in rapid tumor regression. Furthermore, genomic RNA sequencing identified both ligand-dependent and -independent ERβ target genes, some of which were also regulated by ERβ in other TNBC cell lines and correlated with ERβ expression in a cohort of TNBCs from the Cancer Genome Atlas Network. ERβ target genes were enriched in genes that regulate cell death and survival, cell movement, cell development, and growth and proliferation, as well as genes involved in the Wnt/β-catenin and the G1/S cell cycle phase checkpoint pathways. In addition to confirming the anti-proliferative effects of ERβ in TNBC cells, these data provide a comprehensive resource of ERβ target genes and suggest that ERβ may be targeted with ligands that can stimulate its growth inhibitory effects.

UR - http://www.scopus.com/inward/record.url?scp=84884744372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884744372&partnerID=8YFLogxK

U2 - 10.1210/me.2013-1164

DO - 10.1210/me.2013-1164

M3 - Article

VL - 27

SP - 1762

EP - 1775

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 10

ER -